Immunocore Holdings Limited is an innovative biotechnology company based in Abingdon, UK, specializing in the development of advanced immunotherapies targeting cancer, infectious diseases, and autoimmune conditions. Leveraging its proprietary T cell receptor platform, Immunocore is dedicated to enhancing immune responses, thereby delivering transformative therapeutic options that aim to significantly improve patient outcomes. With a robust pipeline of clinical trials and strategic partnerships, the company is well-positioned for growth within the rapidly evolving immunotherapy landscape, presenting attractive opportunities for institutional investors seeking exposure in this critical sector. Show more

Location: 92 PARK DRIVE, ABINGDON, UNITED KINGDOM, OX14 4RY, Abingdon, OX14 4RY, USA | Website: https://www.immunocore.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.645B

52 Wk Range

$23.15 - $40.71

Previous Close

$33.00

Open

$32.42

Volume

761,596

Day Range

$31.68 - $33.26

Enterprise Value

1.188B

Cash

498.4M

Avg Qtr Burn

-4.456M

Insider Ownership

0.03%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Melanoma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Cancer, Melanoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KIMMTRAK (Tebentafusp) +/- anti-PD1 Details Cancer, Melanoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-F106C (Brenetafusp) + nivolumab Details Cancer, Melanoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-R117C [PIWIL1-A02 targeted] Details Cancer, Colorectal cancer , Gastrointestinal stromal tumors	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-F106C (Brenetafusp) Details Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-M113V (Gag-A02) Details Viral infection, Human immunodeficiency virus	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-F106C (Brenetafusp) +/- Pembrolizumab Details Cancer, Melanoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-I109V Details Viral infection, Hepatocellular carcinoma, Hepatitis B	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-P115C (PRAME-HLE-A02) Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-C103C Details Ovarian cancer, Head and neck cancer, Cancer, Non-small cell lung carcinoma, Gastric cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-U120AI Details Atopic dermatitis	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMC-S118AI Details Type 1 Diabetes	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.